FDA's Scott Gottlieb is fielding a new team of recruiters to start scouting top talent
Biotech execs have been bullish supporters of the FDA in recent years, offering their appreciation of faster review times with new programs like the breakthrough therapy designation. But if there’s one recurrent gripe you hear frequently, it’s that the regulators biopharma companies and patient advocates deal with don’t have the right kind of scientific experience for the drugs under review — especially as you stray outside of oncology.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.